

# Eligibility for Abrysvo® and nirsevimab (Beyfortus™)



## NSW RSV Prevention Program

Please distribute to all doctors, nurses and other staff in your practice or service.

### National Immunisation Program: Maternal RSV vaccine Abrysvo®

#### Eligibility

- Abrysvo is the only RSV vaccine available for administration to pregnant women.
- A single dose of Abrysvo should be offered to all pregnant women at the 28-week antenatal visit (recommended between 28 to 36 weeks gestation) and is free under the National Immunisation Program.

#### Other considerations

- Abrysvo can be co-administered with other antenatal vaccinations including diphtheria, tetanus and pertussis (dTpa) vaccine (also given at the 28-week antenatal visit) and influenza vaccines. For further information on co-administration see the [Australian Immunisation Handbook](#).
- Abrysvo is not recommended for use from 24 to less than 28 weeks until additional safety and effectiveness data is available.
- Abrysvo can be given after 36 weeks gestation however infants may not be adequately protected if they are born within 2 weeks of their mother being vaccinated. If delivery occurs within 2 weeks of the mother receiving Abrysvo, the infant is recommended to also receive nirsevimab (see below).

### NSW funded monoclonal antibody: Beyfortus™ (nirsevimab)

Nirsevimab is recommended for infants who are not protected by maternal RSV vaccination and those who have risk conditions for severe RSV disease who meet the following eligibility criteria:

- **Infants born on or after 17 March 2025**
  - to mothers **who did not** receive Abrysvo during pregnancy
  - within 2 weeks of the mother receiving Abrysvo during pregnancy
  - with risk conditions for severe RSV disease<sup>i</sup> regardless of maternal vaccination status
  - to mothers with active malignancies or receiving chemotherapy or taking rituximab or other high-dose immunosuppressive therapy as per the [Australian Immunisation Handbook](#)

- to mothers who have received Abrysvo in pregnancy but have subsequently undergone a treatment, such as cardiopulmonary bypass or extracorporeal membrane oxygenation, that has led to loss of maternal antibodies.

Eligible infants should receive nirsevimab prior to discharge from hospital.

- **Children up to 24 months of age with risk conditions for severe RSV disease<sup>i</sup> entering their second RSV season**, without known prior RSV infection

Eligible children can receive nirsevimab through their local general practitioner (GP), Aboriginal medical service (AMS) or community health service<sup>ii</sup>.

- **NSW RSV Vulnerable Babies Program catch-up for infants born from 1 October 2024 to 16 March 2025**

- **without known prior RSV infection** who meet the following eligibility criteria **and** are not protected through maternal RSV vaccination and did not receive nirsevimab at birth:

- premature infants born less than 37 weeks gestation
- Aboriginal and Torres Strait Islander infants
- infants with risk conditions for severe RSV disease<sup>i</sup>.

Eligible infants can receive nirsevimab through their local GP, AMS or community health service<sup>ii</sup>

---

## Useful resources

For more information refer to:

- [NSW RSV Prevention Program – Information for health professionals](https://www.health.nsw.gov.au/immunisation/Pages/respiratory-syncytial-virus.aspx)  
<https://www.health.nsw.gov.au/immunisation/Pages/respiratory-syncytial-virus.aspx>
- [Clinical decision aid for nirsevimab \(Beyfortus™\) in newborn infants](https://www.health.nsw.gov.au/immunisation/pages/rsv-aid-infants.aspx)  
<https://www.health.nsw.gov.au/immunisation/pages/rsv-aid-infants.aspx>
- [Clinical decision aid for nirsevimab \(Beyfortus™\) in infants and children up to 24 months of age who remain at risk of severe RSV disease](https://www.health.nsw.gov.au/immunisation/pages/rsv-aid-children.aspx)  
<https://www.health.nsw.gov.au/immunisation/pages/rsv-aid-children.aspx>

---

<sup>i</sup> Conditions associated with increased risk of severe RSV disease in infants and young children include:

- preterm birth <32 weeks gestational age
- ongoing haemodynamically significant congenital heart disease
- significant immunosuppression, such as from solid organ transplant, haematopoietic stem cell transplant, or primary immune deficiencies such as severe combined immunodeficiency (SCID) in consultation with a paediatric infectious disease, immunology or immunisation specialist.
- chronic lung disease requiring ongoing oxygen or respiratory support
- neurological conditions that impair respiratory function
- cystic fibrosis with severe lung disease or weight for length <10th percentile
- trisomy 21 or another genetic condition that increases the risk of severe RSV disease.

<sup>ii</sup> GPs, AMSs and community health centres must use the **Nirsevimab Order Form** on the [NSW State Vaccine Centre](#) to order nirsevimab for eligible children.